69 results
8-K
EX-10.2
XLO
Xilio Therapeutics Inc
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
in such Registration Statement.
“Required Investors” means the Investors holding a majority of the Registrable Securities outstanding from time to time
8-K
EX-10.1
8v0mgb18 cz
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
EX-4.1
yatuolzs
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
EX-10.1
bhf4 xzfp3
5 Sep 23
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
8:35am
8-K
EX-99.2
ypr7oey2 da
14 Aug 23
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
7:40am
8-K
EX-10.1
gd61xf
3 Aug 23
Departure of Directors or Certain Officers
4:15pm
8-K
EX-3.1
magdlgqapkaijwszm
3 Apr 23
Departure of Directors or Certain Officers
4:05pm
S-3
EX-4.4
wfq6f 0oveux4u
9 Nov 22
Shelf registration
4:15pm
S-3
EX-4.7
eqjae37kx6wcpn
9 Nov 22
Shelf registration
4:15pm
S-3
EX-4.6
pe9087w qztb9ghezxtk
9 Nov 22
Shelf registration
4:15pm
S-3
r3w2 09zb
9 Nov 22
Shelf registration
4:15pm